Capricor Q3 Loss Widens to $42.7M; Cash Down to $198.5M Ahead of Nov 22 PDUFA
CAPR has more than doubled off its 52-week low of $2.96.
Summary
Capricor posted a $42.7 million third-quarter loss with cash down to $198.5 million from $318.1 million at year-end. Management says that funds at least twelve months of operations as the Deramiocel PDUFA date of November 22, 2026 approaches.
Key Events · Earnings and Guidance · CAPR
-
Q3 Loss Widens to $42.7M
Net loss of approximately $42.7 million, or $0.73 per share, versus $24.6 million, or $0.54 per share, in the third quarter of 2025. Nine-month net loss reached $117.3 million.
-
Cash Falls to $198.5M
Cash, cash equivalents, restricted cash and marketable securities totaled approximately $198.5 million at September 30, 2026, down from $318.1 million at December 31, 2025. No shares were sold under the ATM program from January 1 through November 10, 2026.
-
Spending Climbs on Launch Prep
Third-quarter operating expenses rose to $44.7 million from $26.3 million a year earlier, driven by pre-commercial activities and manufacturing scale-up. A workforce reduction of about 10% was implemented in the quarter.
-
PDUFA Date Set for November 22, 2026
The FDA classified the BLA amendment as a major amendment, extending review by three months to November 22, 2026. A July 2026 BIMO inspection produced a Form 483 with one observation, to which the company has responded.
Analysis · CAPR · Life Sciences
Capricor burned through roughly $120 million in nine months and now holds $198.5 million, which management says covers at least the next twelve months. The real swing factor, however, is the November 22, 2026 PDUFA date for Deramiocel. An approval brings the first revenue and a possible Priority Review Voucher; a rejection leaves a company spending about $45 million a quarter with no product and a distribution dispute heading to arbitration in mid-2027. The 10% workforce cut shows management is already tightening ahead of that binary outcome.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CAPR was trading at $8.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $515.7M. The 52-week trading range was $2.96 to $40.37. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.